We are live on ! Find out more

Immunovant

IMVT

Market cap $7.72B

37.36 USD

-0.74

1.94%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

36.83

-0.53

1.42%

1 day

-1.94%

5 days

-5.27%

1 month

-8.72%

3 months

13.63%

6 months

46.17%

Year to date

44.19%

1 year

122.38%

5 years

329.92%

10 years

275.48%

About: Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Employees: 315

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 55.6%

Negative 0%

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.

Immunovant Q1 Earnings Call Highlights

Zacks Investment Research

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Zacks Investment Research

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?

Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Immunovant Stock Gains 12.4% in a Month: What's Driving It?

IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.

Immunovant Stock Gains 12.4% in a Month: What's Driving It?

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

See News Rankings

Price charts implemented using Lightweight Charts™